| Q35232256 | A cross-sectional study of growth, nutritional status and body proportions in children and adolescents at a medical center specializing in the treatment of cystic fibrosis in Poland. |
| Q34554550 | Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease |
| Q96231866 | Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation |
| Q46259966 | Airway microbiota across age and disease spectrum in cystic fibrosis |
| Q90345066 | Antibiotic Treatment and Age Are Associated With Staphylococcus aureus Carriage Profiles During Persistence in the Airways of Cystic Fibrosis Patients |
| Q35542062 | Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis |
| Q44355443 | Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. |
| Q35589259 | Associations between Gut Microbial Colonization in Early Life and Respiratory Outcomes in Cystic Fibrosis |
| Q44417246 | Bacterial pattern in chronic sinusitis and cystic fibrosis |
| Q99248367 | Bidirectional alterations in antibiotics susceptibility in Staphylococcus aureus-Pseudomonas aeruginosa dual-species biofilm |
| Q37772105 | Cell profile of BAL fluid in children and adolescents with and without lung disease |
| Q38750057 | Characterization of Staphylococcus aureus isolates from pediatric patients with cystic fibrosis. |
| Q54474400 | Chest computed tomography scores in patients with cystic fibrosis colonized with methicillin-resistant Staphylococcus aureus. |
| Q60917956 | Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry |
| Q35669548 | Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients |
| Q34491552 | Clinical significance of microbial infection and adaptation in cystic fibrosis |
| Q35914177 | Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model |
| Q91260289 | Coexistence with Pseudomonas aeruginosa alters Staphylococcus aureus transcriptome, antibiotic resistance and internalization into epithelial cells |
| Q40625603 | Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa |
| Q34470294 | Colonization, competition, and dispersal of pathogens in fluid flow networks |
| Q30413773 | Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. |
| Q40507596 | Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients |
| Q38042719 | Current dilemmas in antimicrobial therapy in cystic fibrosis. |
| Q38911644 | Cystic Fibrosis: Microbiology and Host Response |
| Q47742706 | Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis |
| Q33688123 | Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. |
| Q27027040 | Early pulmonary inflammation and lung damage in children with cystic fibrosis |
| Q57033220 | Elastase Exocytosis by Airway Neutrophils Associates with Early Lung Damage in Cystic Fibrosis Children |
| Q34481869 | Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients |
| Q39403134 | Evolving serodiagnostics by rationally designed peptide arrays: the Burkholderia paradigm in Cystic Fibrosis |
| Q34364700 | Expression of PPARγ and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis |
| Q36197194 | Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus |
| Q91689525 | Help, hinder, hide and harm: what can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections? |
| Q36396848 | Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli |
| Q42017846 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis |
| Q38831274 | In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp. |
| Q92150810 | Intragenic Antimicrobial Peptide Hs02 Hampers the Proliferation of Single- and Dual-Species Biofilms of P. aeruginosa and S. aureus: A Promising Agent for Mitigation of Biofilm-Associated Infections |
| Q38980537 | Low Efficacy of Antibiotics Against Staphylococcus aureus Airway Colonization in Ventilated Patients |
| Q35124580 | Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy. |
| Q55400934 | Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. |
| Q92827965 | Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis |
| Q34412767 | Nontypeable Haemophilus influenzae genetic islands associated with chronic pulmonary infection |
| Q40521169 | Of Pigs, Mice, and Men: Understanding Early Triggers of Cystic Fibrosis Lung Disease |
| Q35666253 | Polymicrobial interactions: impact on pathogenesis and human disease |
| Q36572022 | Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis |
| Q35110113 | Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross-sectional study |
| Q91285393 | Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study |
| Q52847673 | Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis. |
| Q36274268 | Prospective multicenter German study on pulmonary colonization with Scedosporium /Lomentospora species in cystic fibrosis: Epidemiology and new association factors |
| Q89517810 | Pseudomonas aeruginosa Alginate Benefits Staphylococcus aureus? |
| Q36980425 | Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers |
| Q64252399 | Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens |
| Q34065002 | Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases |
| Q34388328 | Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures |
| Q55364460 | Staphylococcus aureus in cystic fibrosis: problem bug or an innocent bystander? |
| Q38130897 | Staphylococcus aureus in early cystic fibrosis lung disease |
| Q37463364 | Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis |
| Q33825634 | The changing microbial epidemiology in cystic fibrosis |
| Q37017741 | The innate immune protein calprotectin promotes Pseudomonas aeruginosa and Staphylococcus aureus interaction. |
| Q34425654 | Three clinically distinct chronic pediatric airway infections share a common core microbiota |
| Q24187701 | Treatment for chronic Staphylococcus aureus pulmonary infection in people with cystic fibrosis |
| Q24186014 | Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis |
| Q57688970 | Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis |
| Q37704053 | Update in cystic fibrosis 2009. |
| Q37608274 | Update on antibiotics for infection control in cystic fibrosis |
| Q40262035 | Vaccine strategies against cystic fibrosis pathogens |
| Q84341387 | [Vaccination of cystic fibrosis patients] |